Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co.'s development plan for STS101 included a completed Phase 1 trial; a Phase 3 efficacy trial (the SUMMIT trial), which is ongoing; and continuation of the open-label, Phase 3 long-term safety trial of STS101 (the ASCEND trial). We show 16 historical shares outstanding datapoints in our STSA shares outstanding history coverage, used to compute STSA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing STSA market cap history over the course of time is important for investors
interested in comparing STSA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of STSA versus a peer is one thing; comparing
STSA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like STSA can fluctuate over the course of history.
With this page we aim to empower investors researching STSA by allowing them to research the STSA market cap history. |
Free STSA Email Alerts:
Video: The Importance of Market Cap
